Notch, Wnt, and Hedgehog  Pathways in Rhabdomyosarcoma: From Single Pathways to an Integrated Network by Roma, Josep et al.
Hindawi Publishing Corporation
Sarcoma
Volume 2012, Article ID 695603, 7 pages
doi:10.1155/2012/695603
Review Article
Notch,Wnt,a n dHedgehog Pathways in Rhabdomyosarcoma:
From Single Pathways to an Integrated Network
Josep Roma,1 AnnaAlmaz´ an-Moga,1 Josep S´ anchez de Toledo,1,2 andSoledadGallego1,2
1Laboratori de Recerca Translacional en el C` ancer Pedi` atric, Hospital Universitari Vall d’Hebron, Universitat Aut` onoma de Barcelona,
Pg Vall d’Hebron 119-129 08035, Spain
2Departament d’Oncologia i Hematologia Pedi` atriques, Hospital Universitari Vall d’Hebron, Universitat Aut` onoma de Barcelona,
Pg Vall d’Hebron 119-129 08035, Spain
Correspondence should be addressed to Soledad Gallego, sgallego@vhebron.net
Received 14 October 2011; Revised 23 December 2011; Accepted 3 January 2012
Academic Editor: Beat W. Sch¨ afer
Copyright © 2012 Josep Roma et al. This is an open access article distributed under the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Rhabdomyosarcoma(RMS)isthemostcommontypeofsofttissuesarcomainchildren.Regardinghistopathologicalcriteria,RMS
can be divided into 2 main subtypes: embryonal and alveolar. These subtypes diﬀer considerably in their clinical phenotype and
molecular features. Abnormal regulation or mutation of signalling pathways that regulate normal embryonic development such
as Notch, Hedgehog, and Wnt is a recurrent feature in tumorigenesis. Herein, the general features of each of the three pathways,
their implication in cancer and particularly in RMS are reviewed. Finally, the cross-talking among these three pathways and the
possibility of better understanding of the horizontal communication among them, leading to the development of more potent
therapeutic approaches, are discussed.
1.Introduction
Rhabdomyosarcoma (RMS) is the most common type of soft
tissue sarcoma in children. RMS can be divided into 2 main
histopathological subtypes: embryonal and alveolar (ERMS
andARMS,resp.).Thesesubtypesdiﬀerconsiderablyintheir
clinical phenotype and molecular features. The prognosis
of ERMS is more favourable than that of ARMS. From a
molecular point of view, the majority of ARMS (80% to
85%) contain one of the reciprocal chromosomal translo-
cations: either t(2;13) (q35;q14) or t(1;13)(p36;q14). These
translocations generate the anomalous fusion genes PAX3-
FOXO1 and PAX7-FOXO1,r e s p e c t i v e l y[ 1, 2]. The resulting
chimerical proteins have potent transforming eﬀects and are
thought to inhibit myogenic diﬀerentiation. However, no
characteristic translocations have been described in ERMS.
The ERMS is typically characterised by loss of heterozygosity
on the short arm of chromosome 11 (11p15.5) [3], and gains
in chromosomes 2, 7, 8, 11, 12, 13, and 17 are also common
in this subtype [4].
Notch, Wnt, and Hedgehog pathways are known to
play critical roles in the development of pluricellular
organisms. Knowledge of the oncogenic role (by mutation
or deregulation) of these pathways has been widening in
recent decades. In paediatric malignancies, evidence of the
possible signiﬁcance of these pathways in the promotion of
oncogenic phenotype has been accumulating. Although the
understanding of the roles played by these pathways in pae-
diatric tumours is advancing, it is far from that of better
known adult malignancies.
2.Notch Signalling
Notch signalling plays a critical role in tissue development in
organisms ranging from nematodes to mammals. The notch
genes encode 4 highly conserved cell surface receptors that
are activated by its ligands (Delta and Jagged in vertebrates).
The Notch intracellular domain (NICD) is then proteolysed
and released by the γ-secretase complex and translocates to
the nucleus where it binds to CSL transcription repressors,
convertingthemintotranscriptionalactivators.Theparadig-
matic targets of these transcription factors in vertebrates are
the HES and HEY genes [5, 6].2 Sarcoma
2.1. Notch and Cancer. The oncogenic potential of the Notch
pathway was ﬁrst described in acute T-cell lymphoblastic
leukaemia (T-ALL) in the late 1980’s. In normal conditions,
Notch signalling is necessary for correct maturation of T-cell
progenitors; however, constitutive activation of the pathway
leads to abnormal T-cell proliferation causing T-ALL [7]. An
abnormal upregulation of the Notch pathway has also been
reported in ovarian [8], breast [9], and other cancers (cervix,
headandneck,endometrium,kidney,lung,pleuralmesothe-
lioma,malignantmelanoma,Hodgkin’slymphoma,anaplas-
tic large cell lymphomas, some acute myeloid leukaemias,
and chronic B-cell lymphocytic leukaemia, among others)
[10]. With respect to paediatric malignancies, Notch signal-
ling appears to contribute essentially to osteosarcoma metas-
tasis [11] and proliferation [12]; Notch signalling also
promotes medulloblastoma cancer stem cell survival [13]
and contributes to angiogenesis in neuroblastoma [14].
2.2. Notch and RMS. During normal muscle development,
the Notch pathway is involved in satellite cell activation and
in cell fate determination during postnatal myogenesis [15].
Activation of Notch pathway is known to inhibit myogenesis
[16, 17]. However, the role of the pathway in RMS is
barely known. Our group recently showed that the Notch
pathway is widely and consistently activated in both ARMS
and ERMS patients; a clear implication in the regulation
of motility and invasiveness of ARMS and ERMS cells was
also reported in the same work [18]. The existence of a
wide range of pharmacological Notch inhibitors renders this
pathway a promising therapeutic target in the ﬁght against
metastases; however, the cross-talk with other pathways such
as Hedgehog and Wnt—as will be discussed below—may
negatively inﬂuence the eﬃcacy of therapeutic approaches if
directed exclusively against one pathway.
3.Hedgehog Signalling
Hedgehog (Hh) signalling was ﬁrst described in 1980 as a
gene exerting a direct eﬀect on embryonic development in
Drosophila [19]. Hedgehog genes are considered to be key
regulators of development in organisms ranging from the
fruit ﬂy to mammals, since they control multiple embryonic
processes such as tissue patterning, proliferation and diﬀer-
entiation. Hedgehog signalling also plays important roles in
adult organisms such as stem cell maintenance and tissue
repair and regeneration. The 3 Hedgehog proteins present
in mammals, Sonic (SHh), Indian (IHh), and Desert (DHh),
need a maturation process to achieve their active forms.
This maturation process implies autocatalytic cleavage of
the protein to release its active N-terminal peptide, with
subsequent N-palmitoylation and the formation of a C-
terminal cholesterol adduct [20]. Mature Hh proteins are
ligands of patched receptors (Ptch1 and Ptch2). Ligand-
free Ptch inhibits the activation of Smoothened (Smo) by
an incompletely known mechanism. The hypothesis that
o n em o l e c u l eo fPtch inhibits one molecule of Smo by
direct binding has been ruled out. Instead, the existence
of endogenous small molecules, gated by Ptch, which are
able to modulate Smo activity, is currently under discussion
[21]. Although the exact endogenous small molecule that
modulates Smo activity has not been identiﬁed, sterol-like
molecules have emerged as leading candidates [21]. In the
absence of active Smo in the membrane, GLI family zinc
ﬁnger proteins (Gli1, Gli2, and Gli3) in a complex with
SuFu (suppressor of fused homolog) are proteosomically
processed. Upon binding of a Hedgehog ligand, active Smo
is detected in the membrane and prevents Gli proteasomal
processing. Gli is then translocated to the nucleus where
it binds to Gli-speciﬁc promoters. Gli1 and Gli2 mainly
function as transcriptional activators, whereas Gli3 exists in
two forms, either as a full-length transcriptional activator
(Gli3A) or an amino-terminal fragment that functions as a
repressor (Gli3R). The three best known direct targets of the
pathwayareGli1, Ptch1, and Hhip, genes of the pathway itself
[21–23].
3.1. Hedgehog and Cancer. The Hedgehog pathway also has
major implications in several cancers. Mutation or dereg-
ulation of the pathway may lead to tumorigenesis in a
wide variety of tissues. The initial link between Hedgehog
signalling and human cancers was established when muta-
tions in human PTCH1 were found to be associated with
a rare hereditary disease called Gorlin’s syndrome. Patients
with Gorlin’s syndrome have a high incidence of basal
cell carcinoma, medulloblastoma, and rhabdomyosarcoma.
The molecular origin of this syndrome is a constitutive
activation of the Hedgehog pathway caused by mutations in
the PTCH1 gene [24, 25]. Hedgehog pathway alterations—
mainly loss of function of Ptch and SuFu or activating
mutations in Smo, Hh, or Gli—are thought to be oncogenic
in a considerable number of other cancers (gliomas, breast,
lung, prostate, ovarian, colon, and endometrial carcinomas,
multiple myeloma, and chronic myeloid leukaemia, among
others) [26].
3.2. Hedgehog and RMS. T h er o l eo fHedgehog signalling
in the genesis of RMS was ﬁrst described in the Patched
knockout mouse by Hahn et al. in 1998 [27]w h or e p o r t e d
t h a tm i c eh e t e r o z y g o u sf o rPtch1 not only develop features
consistent with Gorlin’s syndrome, such as generalised
overgrowth of the body and a variety of neural and skeletal
abnormalities, but also have a high incidence of ERMS.
Tumours in heterozygous Ptch1 mice exhibited elevated
transcript levels of Gli1 and Ptch1 itself, indicating that
abnormal Hedgehog signalling may be common to the
varioustumoursassociatedwithGorlin’ssyndrome[27].The
formation of RMS in Ptch1-mutant mice has been associated
with the ability of tumour cells to resist apoptosis [28]. The
role of epigenetic regulation of Ptch1 expression seemed to
be crucial in heterozygous Ptch1 mice, since a combined
treatment with the DNA-methyltransferase1 inhibitor 5-aza-
2deoxycytidine and the histone deacetylase inhibitor val-
proic acid eﬃciently prevented RMS and medulloblastoma
formation in this model [29]. Currently, a consistent activa-
tion of the pathway is well established and generally accepted
in RMS. A higher degree of Hh activation in ERMS and
translocation-negative ARMS than in translocation-positive
ARMS has also been reported [30]. In the same work, ZibatSarcoma 3
et al. analysed the pathway in a large cohort of RMS patients
and hypothesised that the activation of the pathway confers
poor prognosis in ERMS and translocation-negative ARMS
and suggested an inverse correlation between Hh pathway
activation and muscular diﬀerentiation [30]. Conversely,
Pressey et al. stated recently that neither GLI1 nor PTCH1
mRNAtranscriptsinERMStumourscorrelatedwithsurvival
or other clinical characteristics analysed [31]. Another recent
work showed positive staining by immunohistochemistry
of 78% of samples for SHh, 100% for Ptch, and 78% for
Gli1 in a panel of 18 RMS and reported, in disagreement
with the work of Zibat et al., higher Gli1 expression in
alveolar than in embryonal subtypes [32]. On the other
hand, several publications that combine in vitro and in vivo
works with xenografted rhabdomyosarcoma models agree
about the possibility to eﬀectively reduce tumour growth by
Hh pathway inhibition mediated by betulinic acid, GANT-
61, and forskolin [33–35]. Although these treatments did
not achieve total remission of the tumour, the signiﬁcant
reductionintumourgrowthsuggeststhatHhsignallingplays
a leading role in RMS oncogenicity and that the pathway can
be considered a potential molecular target for new treatment
strategiesinthisneoplasia.Infact,derivativesofcyclopamine
and other small molecular antagonists of Smo have recently
entered clinical phase I and II trials for basal cell carcinoma,
with encouraging results particularly for GDC-0449 [36, 37].
4.Wnt Signalling
The ﬁrst description of the gene Wingless in Drosophila
and the subsequent discovery of its orthologous genes in
vertebrates laid the keystone of an evolutionary conserved
signalling pathway now commonly referred to as the Wnt
pathway. This pathway is involved in the establishment of the
body axis at the earliest stages of embryogenesis and is also
later required for development of many organs in organisms
ranging from C. elegans to mammals. Two variants of the
pathway, canonical and noncanonical, have been described.
The Wnt canonical pathway is generally thought to regulate
cell fate determination and the non-canonical one to control
cell movement and tissue polarity [38].
In the canonical pathway and in the absence of Wnt
ligands, APC and Axin bind to β-catenin (the central actor
in the canonical pathway) thereby permitting its phosphory-
lation by casein kinase I alpha (CKIα)a n dglycogen synthase
kinase 3 beta (GSK3β) and, sequentially, its polyubiquitina-
tion and proteosome-mediated degradation. The interaction
of Wnt ligands with Frizzled receptor and Lrp5/6 coreceptor
inhibits the degradation of β-catenin owing to the formation
of Frizzled-Dishevelled and Lrp5/6-Axin-FRAT complexes
andtheinactivationofGSK3β viaDishevelled(Dvl).Stableβ-
Catenin is translocated to the nucleus where it binds to T-cell
factor/lymphoidenhancerfactor (TCF/LEF)andalsotoLegless
family docking proteins (BCL9 and BCL9L) associated with
PYGO family coactivators, thereby promoting transcription
of the target genes of this pathway: FGF20, DKK1, WISP1,
MYC, and CCDN1, among others [38]. The non-canonical
pathway is also initiated by Wnt ligands (exempliﬁed by
Wnt5aandWnt11)andFrizzledreceptors;however,whilethe
canonicalpathwayleadstoβ-cateninandTCF/LEF-mediated
gene expression, non-canonical Wnt signalling is mainly
mediated by activation of PKC and JNK [39, 40].
4.1. Wnt and Cancer. Anomalous activation of the Wnt
pathway has been reported in several adult cancers such as
non-small-cell lung cancer, colorectal carcinoma, prostate
cancer, and breast cancer among others. Deregulation of
the Wnt pathway in carcinogenesis is often attributed to
am u t a t i o ni nt h eβ1-Catenin gene (CTNNB1). Oncogenic
involvement of the Wnt pathway has also been shown
in diﬀerent embryonal tumours, such as hepatoblastoma,
nephroblastoma (Wilms’ tumour), pancreatoblastoma, and
medulloblastoma.Upto75%ofhepatoblastomasand15%of
Wilms’ tumours display CTNNB1 mutations, approximately
half of which aﬀect exon 3 [41–43]. Other cancer studies
revealed a downregulation of the tumour suppressor Wnt5a,
relatedtothenon-canonicalpathway,thedeletionorreduced
expression of which can occur in several cancers including
sarcomas [44–46].
4.2. Wnt and RMS. Very few works on the role of Wnt
pathwayinRMShavebeenpublished. Soglio etal.concluded
that there was no evidence of β1-Catenin mutation in the
genesis of RMS and that this protein did not constitute a
useful marker for distinguishing between ERMS and ARMS
[47]. Analysis of the CTNNB1 gene sequence in 8 ERMS and
3 ARMS revealed no β1-Catenin mutations in this patient
cohort. In the same work, an immunohistochemical study
of β1-Catenin location showed cytoplasmatic staining with
cytoplasmaticmembranereinforcementandwithoutnuclear
staining [47]. Another work recently published by Singh
et al. provided supporting observations that β1-Catenin-
activatingmutationsdidnotcontributetoERMStumorigen-
esis[48].TheyfoundtheWnt/β1-Cateninsignallingpathway
to be inhibited in an ERMS cell line derived from p53/c-fos
double-mutantmousetumours.Althoughthesecellsshowed
higher expression of Wnt2, Wnt10a, and Wnt8b compared
to normal myoblasts, the most highly overexpressed genes
were Wnt pathway inhibitors such as sFRP2, sFRP4, Dkk1,
and Nkd1. Wnt receptors (Frizzled 1, 3, and 5), the signalling
mediator Dvl and factors involved in recruiting and forming
the activation complex with β1-Catenin in the nucleus (LEF-
1a n dP y g o ) were downregulated. Moreover, the major-
ity of downstream target genes of this pathway showed
no expression diﬀerences compared to normal myoblasts,
thereby suggesting absence of oncogenic activation of the
pathway. On the other hand, some Wnt genes involved in
myogenesis showed an expression pattern that may lead
to impaired muscular diﬀerentiation. Thus, those authors
reported a down-regulation of Wnt7b,w h i c hp r o m o t e s
myogenic diﬀerentiation, and up-regulation of 2 proteins,
sFRP2 and Wnt2, which inhibit myogenic diﬀerentiation.
Furthermore,theactivationoftheWnt pathwayraisedMyoD
and MyHC expression levels and promoted myoblast fusion,
a fact conﬁrming that Wnt signalling directly promotes
myogenic diﬀerentiation [48]. Taken together, the results of
theseexperimentssuggestthattheactivationofWnt pathway
in RMS may mainly promote antioncogenic eﬀects.4 Sarcoma
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Figure 1: Schematic simpliﬁed view of Notch (blue), Wnt (yellow), and Hedgehog (green) signalling pathways and the most signiﬁcant
horizontal interactions among them. Black arrows indicate activating interactions. Red lines indicate inhibiting interactions.
5.Notch, Wnt,a n dHedgehog Compensative
Cross-Talking
A general drawback when pharmacological pathway inhi-
bition is attempted is that only moderate decreases in the
expression of downstream targets are achieved. This obser-
vation is often attributed to incomplete pathway inhibition
by the drugs or compounds used. However, deeper under-
standing of the complex nature of cells and their adeptness at
rewiring molecular circuitry to evade target-speciﬁc agents
may permit the identiﬁcation of new molecular targets
and lead to the development of novel and more powerful
therapeutic approaches.
In support of this idea, Ingram et al. recently reported
in mesodermal and neural cells that Hes1 transcription can
also be activated by Hedgehog ligands by a mechanism that
is absolutely independent of Notch pathway signalling [49].
Therefore, this mechanism of Hes1 activation bypasses γ-
secretaseinhibition—oranyotherkindofNotch inhibition—
and may maintain signiﬁcant Hes1 expression even in the
complete absence of Notch activation. Moreover, the Notch
target Hes1 can directly bind the Gli1 promoter by acting
as a transcriptional repressor and may therefore inﬂuence
Hh signalling in glioblastoma [50]. Interestingly, that work
suggested that γ-secretase-mediated Notch inhibition may
lead to a rise in Gli1 levels which may produce alterationsSarcoma 5
in Hh signalling that in turn may promote tumour survival
by Hh overactivation.
The Notch ligand Jagged1 has also been described as a
link between the Notch and Wnt pathways. The ﬁrst evidence
reported stemmed from an in silico phylogenetic analysis by
which the Jagged1 promoter was identiﬁed as a conserved
targetofWnt/β-Cateninsignallingbasedontheconservation
of speciﬁc consensus binding sites [51]. Three years later,
Rodilla et al. showed Jagged1 to be the pathological link
between the Wnt and Notch pathways in colorectal cancer
[52]. Hence, that work established that Notch can be a down-
stream target of Wnt via β-Catenin-mediated transcriptional
activation of the Notch ligand Jagged1. Other Wnt-pathway-
belonging proteins such as Dvl and GSK3β have also proved
to be involved in a cross-talking with Notch. GSK3β directly
binds to the Notch2 ankyrin repeats in the HEK-293 (human
embryonic kidney 293) cell line [53] while Dvl binds Notch2
within its C-terminal region in Drosophila [54]. In both
cases, Notch activity was reduced. The capability of β-Cat-
enin to modulate the level and transcriptional activity of
Notch1/NICD through its direct interaction has also been
described in HEK-293 cell line [55].
Finally, the ability of the Hedgehog pathway to mod-
ulate Wnt signalling has also been reported. The negative
regulation of Wnt signalling by Gli3R activity has been
described in mouse and chick embryos [56]. Furthermore,
Yanai et al. showed that Gli1 overexpression suppressed Wnt
transcriptional activation and found an inverse correlation
between Wnt and Hh activation in human gastric tumours
[57]. Additionally, the ectopic expression of Gli1 increased
the levels of secreted Frizzled-related protein-1 (sFRP1)b y
direct binding to its promoter in gastric cancer cells [58]. In
colorectal cancer, Gli1 was shown to inhibit the proliferation
ofcancercellsbysuppressingactivationoftheWnt signalling
pathway[59].Themaininteractionsdescribedinthissection
for the three pathways are summarised in Figure 1.
In Notch γ-secretase-mediated inhibition, we observed
that the reduction in Hes1 protein levels in RMS cells in
vitro after GSI treatment was only moderate [18]. Likewise,
the reduction in Hes1 in a RMS xenograft mouse model
treated with γ-secretase inhibitors was also low. The low
inhibition achieved could be explained by low eﬃciency of
the drug or concentration used. Alternatively, the remaining
Hes1 expressionmaybeexplained,atleastinpart,intermsof
compensatory mechanisms based on pathway cross-talking.
Similarly, several works with xenografted rhabdomyosar-
coma models agree on the possibility of reducing, but
not abolishing, tumour growth by Hh pathway inhibition
[33–35]. The compensative activation of other pathways
could explain this partial resistance to Hh-speciﬁc therapies.
The current lack of knowledge on pathway cross-talking in
RMS renders it impossible to substantiate these hypotheses;
however, the information recently gathered on cross-talking
in other tissues may provide us with the guidelines for future
research in this ﬁeld.
Knowledge accumulating in recent years has rendered
the extensive cross-talk among signalling pathways clearly
manifest. The simplistic view of the pathways as linear
entities should give way to a vision of a complex network
formed by longitudinal and transverse interactions as a
prior step towards improvements in future pathway-targeted
therapies. At least in some cancers, deeper understanding of
theadeptnessofcellsatrewiringmolecularcircuitrytoevade
target-speciﬁc therapies should aid the development of more
successful molecular therapies.
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